RecruitingMultiple Myeloma
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Eligible age
30+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Sponsor: Dana-Farber Cancer Institute
You may qualify if…
- ✓ Age ≥ 30 years
- ✓ AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
- ✓ Those over 18 are also eligible if they have 2 or more family members with a blood cancer
You may not qualify if…
- ✕ \* • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
- ✕ Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia
- ✕ First-degree relatives would not need to be identified by the participant.
- ✕ This study includes all special populations who fall within the eligible high-risk age range, ≥ 30 years of age, including adults unable to consent, pregnant women, and prisoners. These populations will not be excluded as this is a non-therapeutic study.
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT03689595 · last updated 2026-05-07